X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (378) 378
Publication (180) 180
Paper (175) 175
Book / eBook (55) 55
Report (14) 14
Book Chapter (12) 12
Newspaper Article (12) 12
Dissertation (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (179) 179
particle physics (175) 175
physics (174) 174
high energy physics - experiment (164) 164
physics - high energy physics - experiment (154) 154
physics of elementary particles and fields (121) 121
physical sciences (113) 113
natural sciences (111) 111
naturvetenskap (111) 111
fysik (110) 110
high energy physics (110) 110
humans (104) 104
index medicus (104) 104
physics, particles & fields (97) 97
female (71) 71
elementary particles, quantum field theory (63) 63
quantum field theories, string theory (63) 63
male (58) 58
phenomenology (58) 58
middle aged (52) 52
aged (47) 47
nuclear experiment (45) 45
collisions (44) 44
hadron-hadron scattering (43) 43
adult (42) 42
detectors (40) 40
物理学 (40) 40
astronomy & astrophysics (38) 38
large hadron collider (38) 38
oncology (37) 37
particle physics - experiment (37) 37
astronomy, astrophysics and cosmology (35) 35
analysis (34) 34
risk factors (34) 34
classical and quantum gravitation, relativity theory (32) 32
quantum physics (32) 32
cern lhc coll (31) 31
measurement science and instrumentation (31) 31
nuclear energy (31) 31
nuclear physics, heavy ions, hadrons (31) 31
cancer (28) 28
experimental results (28) 28
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (27) 27
hep (27) 27
medical and health sciences (27) 27
medicin och hälsovetenskap (27) 27
astrophysics (26) 26
article (24) 24
parton distributions (24) 24
studies (24) 24
subatomic physics (24) 24
subatomär fysik (24) 24
decay (23) 23
luminosity (23) 23
research (23) 23
abridged index medicus (22) 22
disease (22) 22
ex (22) 22
high energy astrophysical phenomena (22) 22
aged, 80 and over (21) 21
standard model (21) 21
age (20) 20
instrumentation and detectors (20) 20
physics, nuclear (20) 20
animals (18) 18
clinical medicine (18) 18
klinisk medicin (18) 18
model (18) 18
population (18) 18
searching (18) 18
transverse momentum (18) 18
health risks (17) 17
instruments & instrumentation (17) 17
lhc (17) 17
medicine (17) 17
medicine, general & internal (17) 17
mortality (17) 17
particle collisions (17) 17
regular - experimental physics (17) 17
health aspects (16) 16
hematology, oncology and palliative medicine (16) 16
jets (16) 16
research article (16) 16
supersymmetry (16) 16
trends (16) 16
charities (15) 15
chemotherapy (15) 15
clinical trials (15) 15
epidemiology (15) 15
higgs bosons (15) 15
leptons (15) 15
treatment outcome (15) 15
care and treatment (14) 14
case-control studies (14) 14
computer simulation (14) 14
hadrons (14) 14
history (14) 14
multidisciplinary sciences (14) 14
pair production (14) 14
protons (14) 14
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (37) 37
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
UofT at Mississauga - Stacks (11) 11
Law (Bora Laskin) - Stacks (8) 8
Gerstein Science - Stacks (6) 6
UTL at Downsview - May be requested (4) 4
UofT at Scarborough - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Faculty of Information - Stacks (3) 3
Knox College (Caven) - Stacks (2) 2
New College (Ivey) - Stacks (2) 2
OISE - Stacks (2) 2
Pontifical Inst. Mediaeval Studies - Library use only (2) 2
Royal Ontario Museum - Stacks (2) 2
Trinity College (John W Graham) - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Physics - Stacks (1) 1
Robarts - Reference (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | ADENOCARCINOMA | CHEMORADIOTHERAPY | FOLINIC ACID | MODEL | CHEMOTHERAPY | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 481 - 489
Summary Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | CETUXIMAB | PROSPECTIVE MULTICENTER | ONCOLOGY | GASTRIC-CANCER | PROGNOSTIC-SIGNIFICANCE | CELL-LINES | METASTATIC COLORECTAL-CANCER | ESOPHAGEAL ADENOCARCINOMA | III TRIAL | Multivariate Analysis | Adenocarcinoma - pathology | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Molecular Targeted Therapy | Esophageal Neoplasms - pathology | Early Termination of Clinical Trials | Organoplatinum Compounds - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Fluorouracil - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Stomach Neoplasms - enzymology | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | United Kingdom | Stomach Neoplasms - drug therapy | Chi-Square Distribution | Adenocarcinoma - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Esophageal Neoplasms - enzymology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Care and treatment | Anthracyclines | Product development | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 749 - 759
Summary Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | COLON-CANCER | 1ST-LINE TREATMENT | LEUCOVORIN | ONCOLOGY | BEVACIZUMAB | PROSPECTIVE MOLECULAR STRATIFICATION | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN | COMBINATION | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Colorectal Neoplasms - enzymology | Camptothecin - therapeutic use | Drug Administration Schedule | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | United Kingdom | Chi-Square Distribution | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Drug Resistance, Neoplasm - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Clinical trials | Care and treatment | Antineoplastic agents | Colorectal cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 601 - 611
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 627 - 637
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 894 - 904
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 317 - 326
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 829 - 840
Summary Background We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in... 
Hematology, Oncology and Palliative Medicine | COLONY-STIMULATING FACTOR | ONCOLOGY | DUCTAL ADENOCARCINOMA | IMMUNOTHERAPY | METAANALYSES | SUPPRESSOR-CELLS | RESISTANT PROSTATE-CANCER | T-CELLS | CHEMOTHERAPY | IPILIMUMAB | TUMOR-ANTIGEN | Cell Proliferation | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Pain - chemically induced | Pancreatic Neoplasms - drug therapy | Fluorouracil - administration & dosage | Female | Neutropenia - chemically induced | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Fluorouracil - analogs & derivatives | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Pancreatic Ducts | Pancreatic Neoplasms - pathology | Peptide Fragments - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Cancer Vaccines - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Telomerase - administration & dosage | Disease-Free Survival | Telomerase - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | T-Lymphocytes - immunology | Aged | Peptide Fragments - adverse effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Hospitals | Gemcitabine | Peptides | Pancreatic cancer | Vaccination | Product development | Vaccines | Metastasis | Telomerase | Cancer
Journal Article